Variable | Total population (N = 28) | EGFR-WT (N = 13) | EGFR-mutant (N = 15) | P |
---|---|---|---|---|
 Sex, no. (%) |  |  |  | 0.13 |
 • Male | 14 (50) | 4 (30.7) | 10 (66.6) |  |
 • Female | 14 (50) | 9 (69.2) | 5 (33.3) |  |
Age (years) | Â | Â | Â | 0.77 |
 • Mean ± SD | 63.6 ± 8.8 | 63.0 ± 9.7 | 64.0 ± 8.2 |  |
BW (kg) | Â | Â | Â | 0.28 |
 • Median | 50.3 | 50.7 | 50 |  |
 • Range | 42—76 | 45—76 | (42—76) |  |
 BMI (kg/m2), no. (%) |  |  |  | 0.43 |
 • Underweight (<18.5) | 3 (10.7) | 0 (0) | 3 (20.0) |  |
 • Normal (18.5–22.9) | 13 (46.4) | 6 (46.1) | 7 (46.6) |  |
 • Overweight (23–24.9) | 6 (21.4) | 4 (30.7) | 2 (13.3) |  |
 • Obese (> 25) | 6 (21.4) | 3 (23.0) | 3 (20.0) |  |
WHO performance status (ECOG), no. (%) | Â | Â | Â | 0.69 |
 • 0 | 7 (25.0) | 2 (15.3) | 5 (33.3) |  |
 • 1 | 19 (67.8) | 10 (76.9) | 9 (60.0) |  |
 • 2 | 2 (7.1) | 1 (7.6) | 1 (6.6) |  |
Smoking status, no. (%) | Â | Â | Â | 0.48 |
 • Never-smoker | 20 (71.4) | 10 (76.9) | 10 (66.6) |  |
 • Ex-smoker | 5 (17.8) | 1 (7.6) | 4 (26.6) |  |
 • Current smoker | 3 (10.7) | 2 (15.3) | 1 (6.67) |  |
Underlying disease, no. (%) | Â | Â | Â | Â |
 • Diabetes mellitus | 5 (17.8) | 3 (23.0) | 2 (13.3) | 0.64 |
 • Hypertension | 12 (42.8) | 6 (46.1) | 6 (40.0) | 0.74 |
 • Dyslipidemia | 7 (25.0) | 1 (7.6) | 6 (40.0) | 0.08 |
 • Chronic obstructive pulmonary disease | 0 (0) | 0 (0) | 0 (0) |  |
 • Inflammatory bowel disease | 0 (0) | 0 (0) | 0 (0) |  |
Previous GI tract surgery, no. (%) | 1 (3.5) | 0 (0) | 1 (6.6) | > 0.99 |
Drug use in past 4Â weeks, no. (%) | Â | Â | Â | Â |
 • Antibiotics | 3 (10.7) | 2 (15.3) | 1 (6.6) | 0.58 |
 • Proton pump inhibitors | 5 (17.8) | 1 (7.6) | 4 (26.6) | 0.33 |
 • Laxatives | 8 (28.5) | 4 (30.7) | 4 (26.6) | > 0.99 |
 • Prebiotics/probiotics | 8 (28.5) | 3 (23.0) | 5 (33.3) | 0.69 |
 • Supplement | 4 (14.2) | 2 (15.3) | 2 (13.3) | 0.78 |
Non-small cell lung cancer Histologic subtype, no. (%) | Â | Â | Â | 0.21 |
 • Adenocarcinoma | 25 (85.2) | 11 (84.6) | 14 (93.3) |  |
 • Squamous cell carcinoma | 2 (7.1) | 2 (15.3) | 0 (0) |  |
 • Adenosquamous cell carcinoma | 1 (3.5) | 0 (0) | 1 (6.67) |  |
Stage at diagnosis, no. (%) | Â | Â | Â | 0.82 |
 • IIIb | 1 (3.5) | 0 (0) | 1 (6.6) |  |
 • IIIc | 2 (7.1) | 1 (7.6) | 1 (6.6) |  |
 • IVa | 19 (67.8) | 10 (76.9) | 9 (60.0) |  |
 • IVb | 6 (21.4) | 2 (15.3) | 4 (26.6) |  |
Albumin (g/dL), no. (%) | Â | Â | Â | 0.02 |
 < 3.2  ≥ 3.2 | 12 (42.8) 16 (57.1) | 9 (69.2) 4 (30.7) | 3 (20.0) 12 (80) |  |
EGFR status, no. (%) | Â | Â | Â | Â |
 • Wild-type |  | 13 (100) | 0 (0) |  |
 • Exon 19 deletion |  |  | 8 (53.3) |  |
 • Exon 21 L858R |  |  | 5 (33.3) |  |
 • Uncommon mutations (G719X, S768I, L861Q) |  |  | 2 (13.3) |  |
Treatment regimen, no. (%) | Â | Â | Â | Â |
 • Carboplatin/paclitaxel |  | 13 (100) |  |  |
 • Gefitinib |  |  | 4 (26.6) |  |
 • Erlotinib |  |  | 4 (26.6) |  |
 • Osimertinib |  |  | 2 (13.3) |  |
 • Others |  |  | 5 (33.3) |  |
Adverse events, no. (%) | Â | Â | Â | 0.66 |
 Grade< 2  Grade≥ 2 | 12 (42.8) 16 (57.1) | 5 (38.4) 8 (61.5) | 7 (46.6) 8 (53.3) |  |